A Randomised, Open-Label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects

Trial Profile

A Randomised, Open-Label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Midazolam; Zibotentan
  • Indications Anxiety disorders; Prostate cancer; Sleep disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Oct 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2008 Status changed from initiated to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top